vs
Side-by-side financial comparison of Outdoor Holding Co (POWW) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $13.4M, roughly 1.0× Outdoor Holding Co). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 16.7%, a 59.0% gap on every dollar of revenue. Outdoor Holding Co produced more free cash flow last quarter ($5.0M vs $-2.1M).
Vista Outdoor Inc. was an American designer, manufacturer, and marketer that operated in two segments: shooting sports and outdoor products. It was a "house of brands" with more than 40 labels and subsidiaries.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
POWW vs XLO — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.4M | $13.7M |
| Net Profit | $2.2M | $10.4M |
| Gross Margin | 87.1% | — |
| Operating Margin | 14.7% | -86.5% |
| Net Margin | 16.7% | 75.7% |
| Revenue YoY | -54.1% | — |
| Net Profit YoY | 108.5% | 179.1% |
| EPS (diluted) | $0.01 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.4M | $13.7M | ||
| Q3 25 | $12.0M | $19.1M | ||
| Q2 25 | $11.9M | $8.1M | ||
| Q1 25 | $12.6M | $2.9M | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $12.0M | — | ||
| Q2 24 | $12.3M | — | ||
| Q1 24 | $-50.7M | — |
| Q4 25 | $2.2M | $10.4M | ||
| Q3 25 | $1.4M | $-16.3M | ||
| Q2 25 | $-6.5M | $-15.8M | ||
| Q1 25 | $-77.5M | $-13.3M | ||
| Q4 24 | $-26.1M | — | ||
| Q3 24 | $-12.4M | — | ||
| Q2 24 | $-14.8M | — | ||
| Q1 24 | $-5.2M | — |
| Q4 25 | 87.1% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 87.2% | — | ||
| Q1 25 | 87.5% | — | ||
| Q4 24 | 87.4% | — | ||
| Q3 24 | 86.9% | — | ||
| Q2 24 | 85.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 14.7% | -86.5% | ||
| Q3 25 | 5.9% | -10.1% | ||
| Q2 25 | -50.7% | -177.7% | ||
| Q1 25 | -213.6% | -472.7% | ||
| Q4 24 | -163.8% | — | ||
| Q3 24 | -50.3% | — | ||
| Q2 24 | -50.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 16.7% | 75.7% | ||
| Q3 25 | 11.7% | -85.4% | ||
| Q2 25 | -54.5% | -196.0% | ||
| Q1 25 | -614.5% | -452.7% | ||
| Q4 24 | -208.7% | — | ||
| Q3 24 | -103.7% | — | ||
| Q2 24 | -120.2% | — | ||
| Q1 24 | 10.3% | — |
| Q4 25 | $0.01 | $-3.74 | ||
| Q3 25 | $0.01 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.16 | ||
| Q1 25 | $-0.67 | $-0.18 | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.11 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $69.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $237.3M | $35.3M |
| Total Assets | $271.7M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $69.9M | $137.5M | ||
| Q3 25 | $65.7M | $103.8M | ||
| Q2 25 | $63.4M | $121.6M | ||
| Q1 25 | $30.2M | $89.1M | ||
| Q4 24 | $31.9M | — | ||
| Q3 24 | $33.5M | — | ||
| Q2 24 | $50.8M | — | ||
| Q1 24 | $55.6M | — |
| Q4 25 | $237.3M | $35.3M | ||
| Q3 25 | $235.4M | $-8.1M | ||
| Q2 25 | $222.5M | $7.1M | ||
| Q1 25 | $222.0M | $10.7M | ||
| Q4 24 | $299.6M | — | ||
| Q3 24 | $325.6M | — | ||
| Q2 24 | $342.5M | — | ||
| Q1 24 | $358.0M | — |
| Q4 25 | $271.7M | $154.7M | ||
| Q3 25 | $270.3M | $133.7M | ||
| Q2 25 | $269.5M | $133.8M | ||
| Q1 25 | $297.3M | $103.7M | ||
| Q4 24 | $355.4M | — | ||
| Q3 24 | $368.9M | — | ||
| Q2 24 | $398.6M | — | ||
| Q1 24 | $403.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | $-2.0M |
| Free Cash FlowOCF − Capex | $5.0M | $-2.1M |
| FCF MarginFCF / Revenue | 37.6% | -15.3% |
| Capex IntensityCapex / Revenue | 4.8% | 0.7% |
| Cash ConversionOCF / Net Profit | 2.55× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.7M | $-2.0M | ||
| Q3 25 | $3.2M | $-17.5M | ||
| Q2 25 | $-6.7M | $-14.5M | ||
| Q1 25 | $-1.5M | $29.0M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $-9.3M | — | ||
| Q2 24 | $-547.5K | — | ||
| Q1 24 | $4.3M | — |
| Q4 25 | $5.0M | $-2.1M | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-7.6M | $-14.9M | ||
| Q1 25 | $-2.3M | $29.0M | ||
| Q4 24 | $720.3K | — | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | 37.6% | -15.3% | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | -63.8% | -184.0% | ||
| Q1 25 | -18.6% | 988.3% | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | -88.3% | — | ||
| Q2 24 | -11.0% | — | ||
| Q1 24 | -2.8% | — |
| Q4 25 | 4.8% | 0.7% | ||
| Q3 25 | 5.8% | 0.0% | ||
| Q2 25 | 7.5% | 5.0% | ||
| Q1 25 | 6.5% | 0.8% | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 10.4% | — | ||
| Q2 24 | 6.5% | — | ||
| Q1 24 | -5.7% | — |
| Q4 25 | 2.55× | -0.19× | ||
| Q3 25 | 2.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
